AdAlta Limited (ASX:1AD) is a highly innovative drug discovery and development company using its powerful technology platform to generate a promising new class of protein therapeutics, known as i-bodies, that have the potential to treat some of today’s most challenging medical conditions.
What is an i-body?
An i-body is a unique human protein that combines the advantages of small molecules (for stability) and antibodies (with a high affinity and specificity for treating certain illnesses) in one powerful treatment. The i-body has a unique long loop that can bind to a diverse range of targets meaning that it has wide applicability across many diseases.
The Company’s lead i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies are sub-optimal. There is a high-unmet medical need for effective treatments.
AdAlta is continuing further discovery and development of the i-body platform, directed towards other disease targets for in-house development or partnering.
Showcase to 300+ investors and pharma at our 5th flagship LSX World Congress.
Plus save £500 before 14th December!
LSX is an influential community of senior life science decision makers. We connect senior life science executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses.